IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
March 05 2024 - 4:30PM
IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical
company developing innovative gamma-delta T cell therapies, today
announced the presentation of new preclinical data for its
non-signaling gamma-delta T cell based Chimeric Antigen Receptor T
cell (CAR-T) platform, INB-300. The data will be presented at the
2024 American Association for Cancer Research (AACR) Annual
Meeting, being held April 5-10, 2024 in San Diego, California.
The current generation of CAR-T technology eliminates the target
antigen regardless of whether it is expressed on tumor or healthy
tissue. IN8bio's nsCAR platform, INB-300, uses the CAR to traffic
and bind to cells expressing the target and leverages the natural
innate immune recognition abilities of gamma-delta T cells to
distinguish between tumor and healthy tissue. This allows the cells
to selectively eliminate cancer cells while leaving healthy cells
intact, even when both express the CAR-target.
“We're excited to share this new data from our nsCAR platform,
INB-300, which enables next-generation precision CAR-T therapy by
selectively targeting leukemia cells while preserving healthy
tissues,” said Lawrence Lamb, Ph.D., co-founder and Chief
Scientific Officer, IN8bio. “We are using gamma-delta T cells to
treat a wide variety of cancers, including myeloid malignancies and
solid tumors, where current CAR-T therapy has historically faced
significant challenges due to on target, but off tumor toxicities.
We look forward to advancing our pipeline of novel gamma-delta
based nsCAR therapies for patients with significant unmet
need.”
AACR Poster Presentation Details
Poster Title: Gamma-delta (γδ) CAR-T cells
lacking the CD3ζ signaling domain enhance targeted killing of AML
cells and preserve healthy tissues
Abstract Presentation Number: 5227
Session Title: Adoptive Cell Therapies 4
Session Date and Time: Tuesday, April 9, 2024,
1:30pm-5:00pm PT (4:30pm-8:00pm ET)
About INB-300INB-300 is a non-signaling CAR
(nsCAR) gamma-delta T cell platform with several preclinical
product candidates, including the INB-330 program against AML
targets, that combine our expertise in gamma-delta T cells and
genetic engineering. These nsCAR constructs lack signaling domains
in order to take advantage of the unique properties of gamma-delta
T cells to differentiate between healthy and tumor tissues. IN8bio
is advancing new nsCAR constructs against multiple targets to treat
both solid and liquid tumors.
About IN8bioIN8bio is a clinical-stage
biopharmaceutical company developing gamma-delta T cell-based
immunotherapies for cancer patients. Gamma-delta T cells are a
specialized population of T cells that possess unique properties,
including the ability to differentiate between healthy and diseased
tissue. The company’s lead program, INB-400, is in a Phase 2 trial
in glioblastoma multiforme (GBM). Additional programs include Phase
1 trials in solid and hematologic tumors, including INB-200 for GBM
and INB-100 for patients with hematologic malignancies undergoing
transplantation. For more information about IN8bio, visit
www.IN8bio.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by words such as
“aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding the ability
of IN8bio’s nsCAR platform to use the innate immune recognition of
gamma-delta T cells to selectively targeting leukemia cells while
preserving healthy tissues; IN8bio’s ability to use gamma delta T
cells to treat a wide variety of cancers, including myeloid
malignancies and solid tumors; and IN8bio’s ability to advance its
pipeline of novel gamma-delta CAR-T therapies. IN8bio may not
actually achieve the plans, intentions, or expectations disclosed
in these forward-looking statements, and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions, and
expectations disclosed in these forward-looking statements as a
result of various factors, including: risks to site initiation,
clinical trial commencement, patient enrollment, and follow-up, as
well as IN8bio’s ability to meet anticipated deadlines and
milestones, presented by public health crises as well as rising
inflation and regulatory developments; uncertainties inherent in
the initiation and completion of preclinical studies and clinical
trials and clinical development of IN8bio’s product candidates; the
risk that IN8bio may not realize the intended benefits of its
DeltEx platform; availability and timing of results from
preclinical studies and clinical trials; whether the outcomes of
preclinical studies will be predictive of clinical trial results;
whether initial or interim results from a clinical trial will be
predictive of the final results of the trial or the results of
future trials; the risk that trials and studies may be delayed and
may not have satisfactory outcomes; potential adverse effects
arising from the testing or use of IN8bio’s product candidates;
expectations for regulatory approvals to conduct trials or to
market products; IN8bio’s reliance on third parties, including
licensors and clinical research organizations; and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements are described in
greater detail in the section entitled “Risk Factors” in our
Quarterly Report on Form 10-Q filed with the Securities and
Exchange Commission (SEC) on November 9, 2023, as well as in other
filings IN8bio may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and IN8bio expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether because of any new information, future events,
changed circumstances, or otherwise, except as otherwise required
by law.
Company Contact:IN8bio,
Inc.Patrick McCall646.600.6438info@IN8bio.com
InvestorsMeru AdvisorsLee M.
Sternlstern@meruadvisors.com
Media ContactKimberly HaKKH
Advisors917.291.5744kimberly.ha@kkhadvisors.com
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Sep 2024 to Oct 2024
IN8bio (NASDAQ:INAB)
Historical Stock Chart
From Oct 2023 to Oct 2024